Woodline Partners’s West Pharmaceutical WST Stock Holding History

Woodline Partners’s Portfolio WST Stock Details WST Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$5.56M	Buy	15,498 +12,692	+452%	+$3.88M	0.02%	671
2026 Q1	$703K	Sell	2,806 -7,282	-72%	-$1.81M	﹤0.01%	923
2025 Q4	$2.78M	Sell	10,088 -242,128	-96%	-$66.2M	0.01%	732
2025 Q3	$66.2M	Buy	+252,216	New	+$61.3M	0.31%	67
2025 Q2	–	Sell	-138,871	Closed	-$31.1M	–	1064
2025 Q1	$31.1M	Buy	138,871 +119,417	+614%	+$32.9M	0.2%	154
2024 Q4	$6.37M	Buy	+19,454	New	+$6.12M	0.04%	438
2024 Q2	–	Sell	-166,588	Closed	-$65.9M	–	689
2024 Q1	$65.9M	Buy	166,588 +147,018	+751%	+$54.4M	0.61%	39
2023 Q4	$6.89M	Buy	+19,570	New	+$6.93M	0.07%	273
2023 Q2	–	Sell	-81,725	Closed	-$28.3M	–	764
2023 Q1	$28.3M	Buy	81,725 +32,453	+66%	+$9.48M	0.39%	78
2022 Q4	$11.6M	Buy	+49,272	New	+$11.7M	0.16%	186
2021 Q1	–	Sell	-33,980	Closed	-$9.63M	–	480
2020 Q4	$9.63M	Buy	+33,980	New	+$9.54M	0.26%	118

Other funds holding WST

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

GIM

Generation Investment Management London, United Kingdom $10.3B AUM 4.84% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Woodline Partners's WST Position: Q2 2026 in Review

Woodline Partners increased its West Pharmaceutical (WST) stake by 452% in Q2 2026, buying an estimated $3.88M and bringing the position to 15,498 shares worth $5.56M. The position accounts for 0.02% of the portfolio, ranked #671.

Woodline Partners first reported a position in WST in Q4 2020 and has held it in 11 quarters since. The position peaked at $66.2M in Q3 2025. 831 funds tracked by Wall St. Rank hold WST as of Q2 2026.

Woodline Partners held 15,498 shares of West Pharmaceutical worth $5.56M as of Q2 2026.
Woodline Partners bought 12,692 West Pharmaceutical shares in Q2 2026, an estimated $3.88M.
West Pharmaceutical made up 0.02% of Woodline Partners's portfolio in Q2 2026, its #671 holding.
Woodline Partners first reported a position in West Pharmaceutical in Q4 2020 and has held it in 11 quarters since.
Woodline Partners's West Pharmaceutical position peaked at $66.2M in Q3 2025.
831 funds tracked by Wall St. Rank held West Pharmaceutical as of Q2 2026.

Based on Woodline Partners's 13F filing for Q2 2026, filed 14 Aug 2026.